Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002638040 | SCV003517073 | uncertain significance | Glycogen storage disease XV; Polyglucosan body myopathy type 2 | 2023-08-04 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 2197883). This variant has not been reported in the literature in individuals affected with GYG1-related conditions. This variant is present in population databases (rs141679018, gnomAD 0.05%). This sequence change replaces aspartic acid, which is acidic and polar, with tyrosine, which is neutral and polar, at codon 346 of the GYG1 protein (p.Asp346Tyr). |
Ambry Genetics | RCV002638041 | SCV003723482 | uncertain significance | Inborn genetic diseases | 2021-08-13 | criteria provided, single submitter | clinical testing | The c.1036G>T (p.D346Y) alteration is located in exon 8 (coding exon 8) of the GYG1 gene. This alteration results from a G to T substitution at nucleotide position 1036, causing the aspartic acid (D) at amino acid position 346 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |